Tag: CPAP
In brief: Trace Medical acquisition, HealthTap launch, Accendra Health notice
October 13, 2026HME News Staff
WHITMORE LAKE, Mich. & SARASOTA, Fla. – Trace Medical has acquired a majority interest in LiViliti Health Products, Inc. The acquisition follows LiViliti receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360 classified as a Class II Respiratory Accessory Microbial Reduction Device for CPAP equipment.
The acquisition builds upon the existing strategic investment between the two organizations, aligning Trace Medical’s expansive nationwide distribution...
In brief: PAP recall, indie outlook, OTC sensor, Kalogon hire
October 6, 2026HME News Staff
WASHINGTON – BMC Medical retrospectively reported to the U.S. Food and Drug Administration (FDA) a recall of 20,160 Luna G3 APAP devices (model LG3600) distributed in the United States due to a firmware defect, the agency has reported.
The FDA has classified it as a Class I recall (FDA Recall Number: Z-2979-2026).
BMC has identified that the firmware version G3-2.00.76 with configuration G3 A20-31.cfg that is installed on these Luna devices contained a debug code. The company conducted...
GLP-1s show promise as complement to CPAP for sleep apnea, researchers say
September 29, 2026HME News Staff
YARMOUTH, Maine – GLP-1 receptor agonists like tirzepatide are best used to treat obesity-related obstructive sleep apnea (OSA) alongside CPAP, according to a new abstract in JAMA Otolaryngology – Head & Neck Surgery. Researchers found that multiple studies showed the medications consistently reduced apnea-hypopnea index (AHI) scores, with the SURMOUNT-OSA trials reporting reductions of 20 to 24 events per hour and disease remission in 42% to 50% of patients. The drugs appear to work...
In brief: CGMs are essential & effective, GLP-1s & CPAP are better together
September 25, 2026HME News Staff
MILAN – A majority of health care providers (HCPs) recognize continuous glucose monitoring (CGM) as essential to Type 2 diabetes management, according to a new report published by Dexcom ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan Sept. 28-Oct. 2.
Eighty-nine percent of HCPs believe CGM helps them assess treatment adherence between appointments, and more than half of current CGM users report they have followed their treatment plan...
SoClean launches national TV commercial featuring Barry the bacteria
September 14, 2026HME News Staff
MINNEAPOLIS – SoClean has launched a new national TV campaign in partnership with Marketing Architects, bringing its SoClean 3+ to market with a commercial told from the perspective of the bacteria the product reduces. SoClean says the 3+ is the first and only device cleared by the U.S. Food and Drug Administration (FDA) that reduces 99.9% of bacteria on compatible home-use CPAP hoses and masks after cleaning. "CPAP hoses and masks can trap and grow bacteria over time,” said Robert...
ReDream CEO: Consolidation unlocks ‘enormous’ untapped opportunity in sleep market
August 28, 2026Theresa Flaherty
NEW YORK – Bringing together four direct-to-consumer sleep brands under one umbrella will create a scalable platform to reach “an enormous amount of untapped opportunity,” says Joe Megibow, CEO of the recently launched ReDream Brands.
“I think any one of these businesses could double or triple their business without adding a ton of overhead,” he said. “The hard part is getting that reach – you can’t just go from one to 10 overnight. That’s...
Study links untreated OSA to faster cognitive decline
July 16, 2026HME News Staff
GAINESVILLE, Fla. - Older adults with untreated obstructive sleep apnea (OSA) experienced faster cognitive decline over 10 years than those treated with CPAP, according to a study published in Alzheimer’s & Dementia. Researchers analyzed 777 participants from the 2011 National Health and Aging Trends Study who had at least one Medicare claim for OSA and no cognitive impairment at baseline. CPAP treatment was defined as having one or more CPAP claims. The researchers tracked cognitive performance...
In brief: CPAP’s adherence assumption, CGM’s benefits, Shaq’s sleep apnea
June 12, 2026HME News Staff
ORLANDO, Fla. – Many insurers stop covering continuous positive airway pressure (CPAP) devices if patients don’t use them regularly in the first 90 days. But new research presented at the ATS 2026 International Conference shows that many patients who initially struggle to meet these early-use thresholds do go on to use and benefit from CPAP therapy.
The findings challenge long-held assumptions that poor early use predicts long-term CPAP use, said first author Dennis Hwang, MD, a sleep...
New research questions Medicare’s 90-day rule for CPAP adherence
June 11, 2026HME News Staff
ORLANDO, Fla. – Many insurers stop covering continuous positive airway pressure (CPAP) devices if patients don’t use them regularly in the first 90 days. But new research presented at the ATS 2026 International Conference shows that many patients who initially struggle to meet these early-use thresholds do go on to use and benefit from CPAP therapy.
The findings challenge long-held assumptions that poor early use predicts long-term CPAP use, said first author Dennis Hwang, MD, a sleep...
Sleep therapy growth at inflection point
June 10, 2026HME News Staff
Sleep therapy is expanding across new channels, technologies and care settings, creating more ways than ever to diagnose and treat obstructive sleep apnea – and giving providers new opportunities to shape the patient journey, despite its growing complexity, industry experts say.
“Demand remains strong because obstructive sleep apnea continues to be significantly underdiagnosed, but the pathway into therapy is changing rapidly,” said Robin Randolph, senior vice president of sales...